MX9804106A - Sales de derivados de quinolina como antagonistas de nk3. - Google Patents
Sales de derivados de quinolina como antagonistas de nk3.Info
- Publication number
- MX9804106A MX9804106A MX9804106A MX9804106A MX9804106A MX 9804106 A MX9804106 A MX 9804106A MX 9804106 A MX9804106 A MX 9804106A MX 9804106 A MX9804106 A MX 9804106A MX 9804106 A MX9804106 A MX 9804106A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonists
- compound
- salts
- quinoline derivatives
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de la formula (I) (Ver Formula) o un solvato del mismo, caracterizado además porque la sal comprende un compuesto de la formula (I) en forma anionica y un cation formador de sal; un procedimiento para preparar dicho compuesto, una composicion farmacéutica que contiene dicho compuesto y el uso de dicho compuesto en medicina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9524137.8A GB9524137D0 (en) | 1995-11-24 | 1995-11-24 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9804106A true MX9804106A (es) | 1998-09-30 |
Family
ID=10784449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9804106A MX9804106A (es) | 1995-11-24 | 1998-05-22 | Sales de derivados de quinolina como antagonistas de nk3. |
Country Status (23)
Country | Link |
---|---|
US (3) | US6355654B1 (es) |
EP (1) | EP0876348B1 (es) |
JP (1) | JP4377454B2 (es) |
KR (1) | KR19990071599A (es) |
CN (1) | CN1207728A (es) |
AR (1) | AR004970A1 (es) |
AT (1) | ATE233243T1 (es) |
AU (1) | AU722451B2 (es) |
BR (1) | BR9611729A (es) |
CA (1) | CA2238312A1 (es) |
CZ (1) | CZ158198A3 (es) |
DE (1) | DE69626416T2 (es) |
ES (1) | ES2192621T3 (es) |
GB (1) | GB9524137D0 (es) |
HU (1) | HUP9903584A3 (es) |
IL (1) | IL124352A0 (es) |
MX (1) | MX9804106A (es) |
NO (1) | NO310866B1 (es) |
NZ (1) | NZ323389A (es) |
PL (1) | PL326927A1 (es) |
TR (1) | TR199800925T2 (es) |
WO (1) | WO1997019928A1 (es) |
ZA (1) | ZA969812B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9825554D0 (en) * | 1998-11-20 | 1999-01-13 | Smithkline Beecham Spa | Novel Compounds |
US7037922B1 (en) * | 2000-03-10 | 2006-05-02 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
DE60004654T2 (de) | 1999-03-29 | 2004-06-24 | Neurogen Corp., Branford | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden |
AU4802500A (en) * | 1999-04-26 | 2000-11-10 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
CN101189211A (zh) * | 2005-06-03 | 2008-05-28 | 阿斯利康(瑞典)有限公司 | 作为nk3拮抗剂的喹啉衍生物 |
GB0515580D0 (en) | 2005-07-29 | 2005-09-07 | Merck Sharp & Dohme | Therapeutic compounds |
JP2009504572A (ja) * | 2005-08-02 | 2009-02-05 | スミスクライン・ビーチャム・コーポレイション | キノリン誘導体の合成方法 |
EP1915363A1 (en) * | 2005-08-11 | 2008-04-30 | AstraZeneca AB | Oxopyridyl quinoline amides as nk3 receptor modulators |
AR057130A1 (es) * | 2005-09-21 | 2007-11-14 | Astrazeneca Ab | Quinolinas de alquilsulfoxido y una composicion farmaceutica |
JP2009508944A (ja) * | 2005-09-21 | 2009-03-05 | アストラゼネカ・アクチエボラーグ | Nk−3受容体リガンドとしてのn−オキソ複素環及びn−オキソ−アルキルキノリン−4−カルボキシアミド類 |
TW201018662A (en) | 2005-12-12 | 2010-05-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
US20090054445A1 (en) * | 2006-01-27 | 2009-02-26 | Astrazeneca Ab | Amide Substituted Quinolines |
FR2979173B1 (fr) * | 2011-08-19 | 2013-08-16 | St Microelectronics Grenoble 2 | Commutateur analogique basse tension |
RU2610262C2 (ru) | 2011-11-03 | 2017-02-08 | Мерк Шарп И Доум Корп. | ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGLuR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ |
US9475773B2 (en) | 2013-04-19 | 2016-10-25 | Astrazeneca Ab | NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS) |
WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL186665B1 (pl) | 1994-05-27 | 2004-02-27 | Smithkline Beecham Spa | Pochodne chinoliny jako antagoniści receptorów NKtachykininy, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca pochodne chinoliny oraz ich zastosowanie |
IT1270615B (it) * | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
-
1995
- 1995-11-24 GB GBGB9524137.8A patent/GB9524137D0/en active Pending
-
1996
- 1996-11-21 AR ARP960105281A patent/AR004970A1/es unknown
- 1996-11-22 TR TR1998/00925T patent/TR199800925T2/xx unknown
- 1996-11-22 WO PCT/EP1996/005210 patent/WO1997019928A1/en not_active Application Discontinuation
- 1996-11-22 AT AT96941026T patent/ATE233243T1/de not_active IP Right Cessation
- 1996-11-22 CN CN96199611A patent/CN1207728A/zh active Pending
- 1996-11-22 BR BR9611729A patent/BR9611729A/pt unknown
- 1996-11-22 NZ NZ323389A patent/NZ323389A/en unknown
- 1996-11-22 KR KR1019980703875A patent/KR19990071599A/ko not_active Application Discontinuation
- 1996-11-22 ZA ZA9609812A patent/ZA969812B/xx unknown
- 1996-11-22 US US09/077,152 patent/US6355654B1/en not_active Expired - Fee Related
- 1996-11-22 JP JP52016097A patent/JP4377454B2/ja not_active Expired - Fee Related
- 1996-11-22 EP EP96941026A patent/EP0876348B1/en not_active Expired - Lifetime
- 1996-11-22 CZ CZ981581A patent/CZ158198A3/cs unknown
- 1996-11-22 ES ES96941026T patent/ES2192621T3/es not_active Expired - Lifetime
- 1996-11-22 DE DE69626416T patent/DE69626416T2/de not_active Expired - Lifetime
- 1996-11-22 CA CA002238312A patent/CA2238312A1/en not_active Abandoned
- 1996-11-22 AU AU10319/97A patent/AU722451B2/en not_active Ceased
- 1996-11-22 IL IL12435296A patent/IL124352A0/xx unknown
- 1996-11-22 HU HU9903584A patent/HUP9903584A3/hu unknown
- 1996-11-22 PL PL96326927A patent/PL326927A1/xx unknown
-
1998
- 1998-05-22 NO NO19982332A patent/NO310866B1/no not_active IP Right Cessation
- 1998-05-22 MX MX9804106A patent/MX9804106A/es unknown
-
2001
- 2001-11-06 US US09/994,076 patent/US6432977B1/en not_active Expired - Fee Related
-
2002
- 2002-06-12 US US10/167,881 patent/US20020156097A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR9611729A (pt) | 1999-04-06 |
PL326927A1 (en) | 1998-11-09 |
EP0876348A1 (en) | 1998-11-11 |
US6432977B1 (en) | 2002-08-13 |
NO982332D0 (no) | 1998-05-22 |
NZ323389A (en) | 2000-02-28 |
AU722451B2 (en) | 2000-08-03 |
DE69626416D1 (de) | 2003-04-03 |
CA2238312A1 (en) | 1997-06-05 |
WO1997019928A1 (en) | 1997-06-05 |
JP2000500770A (ja) | 2000-01-25 |
US20020156097A1 (en) | 2002-10-24 |
KR19990071599A (ko) | 1999-09-27 |
NO982332L (no) | 1998-05-22 |
US6355654B1 (en) | 2002-03-12 |
AU1031997A (en) | 1997-06-19 |
NO310866B1 (no) | 2001-09-10 |
DE69626416T2 (de) | 2003-12-24 |
ATE233243T1 (de) | 2003-03-15 |
HUP9903584A3 (en) | 2001-10-29 |
JP4377454B2 (ja) | 2009-12-02 |
CZ158198A3 (cs) | 1998-10-14 |
GB9524137D0 (en) | 1996-01-24 |
CN1207728A (zh) | 1999-02-10 |
EP0876348B1 (en) | 2003-02-26 |
ES2192621T3 (es) | 2003-10-16 |
US20020077335A1 (en) | 2002-06-20 |
HUP9903584A2 (hu) | 2000-02-28 |
AR004970A1 (es) | 1999-04-07 |
ZA969812B (en) | 1998-05-22 |
IL124352A0 (en) | 1998-12-06 |
TR199800925T2 (xx) | 2001-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9804106A (es) | Sales de derivados de quinolina como antagonistas de nk3. | |
AU645709B2 (en) | New 2,4-thiazolidinedione compounds, process for preparing them and pharmaceutical compositions containing them | |
PH31566A (en) | Pyridine and pyridine n-oxide derivatives for diaryl methyl piperidines or piperazines and compositions and methods of use thereof. | |
MX9804107A (es) | Derivados de quinolina. | |
MY115416A (en) | Quinolone-and naphthyridone-carboxylic acid derivatives | |
IL104559A0 (en) | N-sulfonyl-2-oxoindole derivatives,their preparation and pharmaceutical compositions containing them | |
MY128809A (en) | Pharmaceutical formulation of omeprazole | |
IL114599A0 (en) | Substituted pyrimidine compounds their preparation and pharmaceutical compositions containing them | |
MX9503529A (es) | Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen. | |
HUT72970A (en) | Risperidone pamoate, pharmaceutical composition containing it and process for their production | |
HUT68092A (en) | Substituted heterocyclyl isoquinolinium salts, process for their production and pharmaceutical compositions containing the same | |
UA19782A (uk) | Спосіб одержаhhя біциклічhих складhих ефірів або їх фармацевтичhо прийhятhих солей | |
MX9706605A (es) | Derivados de indol como antagonistas de los aminoacidos exitadores. | |
ZA922297B (en) | Crystalline tiababine monohydrate,its preparation and use | |
HUP9903492A3 (en) | Quinoline derivatives as type iv phosphodiesterase inhibitors, process for their preparation, pharmaceutical compositions containing the same and their use | |
AU9122691A (en) | 1-(4-acylaminophenyl)-7,8-methylenedioxy-5h-2,3-benzo-diazep ine derivatives and acid addition salts thereof, pharmaceutical compositions containing them and process for preparing same | |
NZ236293A (en) | 1-(alkyl or alkoxyalkyl)-4-phenyl piperidine-4-carboxylic acid amide derivatives; preparatory processes and pharmaceutical compositions | |
HUP9802492A3 (en) | Benzisoxazole and indazole derivatives as antipsychotic agents, process for their preparation and pharmaceutical compositions containing the same | |
IL113365A0 (en) | 5-heterocyclo-1,5-benzodiazepine derivatives, their preparation and use and pharmaceutical compositions containing them | |
MY135774A (en) | Hexahydroazepine derivatives, a process for their preparation and pharmaceutical compositions containing them. | |
TW252979B (es) | ||
AU1998995A (en) | Substituted fused and bridged bicyclic compounds as therapeutic agents | |
EP0521393A3 (en) | Diclofenac salt, a method for the preparation thereof and pharmaceutical compositions containing it | |
ES2022006A6 (es) | Procedimiento para la preparacion de compuestos de acidos piridona carboxilicos azetidinil substituidos. | |
CA2360894A1 (en) | (1-phenacyl-3-phenyl-3-piperidylethyl) piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same |